Want to see ENLV full AI Analyst Report?
ENLV Stock Chart & Stats
$1.52
-$0.06(-1.43%)
At close: 4:00 PM EDT
$1.52
-$0.06(-1.43%)
Day’s Range― - ―
52-Week Range$0.17 - $27.15
Previous CloseN/A
Volume17.00K
Average Volume (3M)1.84M
Market Cap
$3.45M
Enterprise Value$28.67M
Total Cash (Recent Filing)$5.52M
Total Debt (Recent Filing)$17.25M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)577.48
Shares Outstanding19,908,590
10 Day Avg. Volume620,947
30 Day Avg. Volume1,841,233
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap8.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-133.95
Enterprise Value/Ebitda-1.44
Forecast
1Y Price Target
$80.00Price Target Upside5163.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical StrategyConcentrating resources on one lead clinical program can improve execution discipline and reduce fragmented spending. Allocetra™ also has positive Phase 1/2a results and RMAT backing, providing meaningful development validation while the Phase 2b trial advances toward a significant clinical readout.
Cost ReductionThe restructuring should reduce the operating cost base and preserve capital for the highest-priority trial. Lower management pay and a smaller workforce demonstrate willingness to align expenses with available resources, potentially extending the company’s ability to fund clinical development over coming quarters.
Low Historical LeverageVery low reported leverage and substantial equity provide a stronger solvency foundation than many development-stage biotech companies. This balance-sheet profile can improve flexibility to fund research, absorb operating losses, and manage financing needs while clinical milestones remain uncertain.
Bears Say
No Commercial RevenueThe absence of revenue confirms that Enlivex has not yet established a commercial product or self-sustaining business model. Continued operating losses mean future progress depends on clinical success and access to capital, leaving earnings power highly dependent on unproven pipeline outcomes.
Persistent Cash BurnOngoing negative operating and free cash flow shows that the business cannot currently finance itself through operations. Although the burn rate improved from earlier periods, continued funding needs can constrain strategic choices, require additional financing, and increase pressure to prioritize only the most advanced program.
Volatile Earnings QualityLarge non-operating digital-asset gains do not demonstrate improvement in the underlying biotech business, especially while revenue remains absent and operating expenses continue. Expanding crypto exposure, deferred taxes, and derivative liabilities can make reported results more volatile and complicate assessment of durable earnings.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $0.17 and its highest was $27.15 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $3.45M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 179 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -$0.02 earnings per share for the quarter.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 19,908,590 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.02 in its last earnings report. Following the earnings report the stock price went down -0.38%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
ENLV Stock 12 Month Forecast
Average Price Target
$80.00
▲(5163.16% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.15% Mutual Funds
<0.01% Other Institutional Investors
99.84% Public Companies and
Individual Investors